297 related articles for article (PubMed ID: 28069654)
1. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.
van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654
[TBL] [Abstract][Full Text] [Related]
2. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
[TBL] [Abstract][Full Text] [Related]
3. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.
Dijkstra JA; van Altena R; Akkerman OW; de Lange WC; Proost JH; van der Werf TS; Kosterink JG; Alffenaar JW
Int J Antimicrob Agents; 2015 Sep; 46(3):332-7. PubMed ID: 26228464
[TBL] [Abstract][Full Text] [Related]
4. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
5. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.
Modongo C; Sobota RS; Kesenogile B; Ncube R; Sirugo G; Williams SM; Zetola NM
BMC Infect Dis; 2014 Oct; 14():542. PubMed ID: 25300708
[TBL] [Abstract][Full Text] [Related]
6. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
Arnold A; Cooke GS; Kon OM; Dedicoat M; Lipman M; Loyse A; Chis Ster I; Harrison TS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696239
[TBL] [Abstract][Full Text] [Related]
7. Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB).
Sabur NF; Brar MS; Wu L; Brode SK
BMC Infect Dis; 2021 Mar; 21(1):254. PubMed ID: 33691624
[TBL] [Abstract][Full Text] [Related]
8. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.
Alsaad N; van Altena R; Pranger AD; van Soolingen D; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
Eur Respir J; 2013 Aug; 42(2):504-12. PubMed ID: 23100498
[TBL] [Abstract][Full Text] [Related]
10. Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
Sturkenboom MGG; Simbar N; Akkerman OW; Ghimire S; Bolhuis MS; Alffenaar JC
Clin Infect Dis; 2018 Nov; 67(suppl_3):S303-S307. PubMed ID: 30496466
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
Van't Boveneind-Vrubleuskaya N; Seuruk T; van Hateren K; van der Laan T; Kosterink JGW; van der Werf TS; van Soolingen D; van den Hof S; Skrahina A; Alffenaar JC
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507117
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
[TBL] [Abstract][Full Text] [Related]
13. Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin).
Mirza IA; Khan FA; Khan KA; Satti L; Ghafoor T; Fayyaz M
J Coll Physicians Surg Pak; 2015 May; 25(5):337-41. PubMed ID: 26008658
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
[TBL] [Abstract][Full Text] [Related]
15. Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
Melchionda V; Wyatt H; Capocci S; Garcia Medina R; Solamalai A; Katiri S; Hopkins S; Cropley I; Lipman M
Eur Respir J; 2013 Oct; 42(4):1148-50. PubMed ID: 24081766
[No Abstract] [Full Text] [Related]
16. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
17. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
Tabarsi P; Chitsaz E; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Amiri M; Mansouri D; Masjedi MR; Velayati AA; Caminero JA
Microb Drug Resist; 2010 Mar; 16(1):81-6. PubMed ID: 20192820
[TBL] [Abstract][Full Text] [Related]
18. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
de Jager P; van Altena R
Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
[TBL] [Abstract][Full Text] [Related]
20. Hearing loss in children treated for multidrug-resistant tuberculosis.
Seddon JA; Thee S; Jacobs K; Ebrahim A; Hesseling AC; Schaaf HS
J Infect; 2013 Apr; 66(4):320-9. PubMed ID: 22960077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
